NMRA
Neumora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
+3.47%Oct 30, 2026, 20:26 UTC
NASDAQ, INC. notified Neumora Therapeutics that it was not in compliance with Listing Rule 5450(a)(1) because of its share price, giving the company until April 26, 2027, to regain compliance.
Aug 14, 2026, 00:00 UTC
Paul L. Berns stepped down as Executive Chairperson of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.
Aug 14, 2026, 00:00 UTC
Doron Sagman, M.D., FRCPC was appointed Chief Medical Officer of Neumora Therapeutics, Inc., effective August 14, 2026.
Aug 14, 2026, 00:00 UTC
Joshua Pinto, Ph.D. was promoted to Chief Executive Officer and President, and Class III director of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.
Jun 15, 2026, 12:00 UTC
Neumora Therapeutics reported that navacaprant failed to meet primary endpoints in Phase 3 KOASTAL-2 and -3 trials for major depressive disorder, leading to discontinuation of its development.
Jun 15, 2026, 00:00 UTC
Neumora Therapeutics amended its loan and security agreement with K2 HealthVentures LLC, extending the interest-only payment period and revising the minimum liquidity covenant.